Gamma Secretase Inhibitors and Modulators
- Name
- Gamma Secretase Inhibitors and Modulators
- Accession Number
- DBCAT005541
- Description
Agents that suppress GAMMA-SECRETASE by inhibiting or modulating its activities. Targeted enzymatic activities include its involvement in accumulation of toxic AMYLOID BETA-PEPTIDES (e.g., Aβ42) in ALZHEIMER DISEASE and activation of NOTCH RECEPTOR mediated SIGNAL PATHWAYS in certain cancer types.
- Drugs
Drug Drug Description E-2012 Investigated for use/treatment in alzheimer's disease. Avagacestat Avagacestat has been investigated for the basic science and treatment of Alzheimer Disease. Nirogacestat A gamma-secretase inhibitor used to treat desmoid tumors Begacestat Begacestat has been used in trials studying the treatment and basic science of Alzheimer Disease. Semagacestat Semagacestat has been used in trials studying the treatment of Alzheimer Disease. MK-0752 Mk 0752 is under investigation in clinical trial NCT00572182 (MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer). BMS-986115 BMS-986115 has been used in trials studying the treatment of Various Advanced Cancer. Tarenflurbil Investigated for use/treatment in alzheimer's disease and prostate cancer. RG-4733 Ro4929097 has been used in trials studying the treatment of Sarcoma, LYMPHOMA, Neoplasms, Wilm's Tumor, and OSTEOSARCOMA, among others. Itanapraced Not Annotated MRK-003 MRK-003 is a potent and selective γ-secretase inhibitor developed by Merck. It is the preclinical analog of MK-0752, a drug in clinical development. - Drugs & Drug Targets